Targeted Oncology |
Ruxolitinib Beats Out Best Available Therapy in Polycythemia Vera
Targeted Oncology The study enrolled patients with PV who required a phlebotomy for hematocrit control, had a spleen volume of ≥450 cm3, and had never received treatment with a JAK inhibitor.2 Overall, 222 patients were randomized 1:1 to receive either ruxolitinib (n ... |
from phlebotomy - Google News http://bit.ly/2df8mlY
No comments:
Post a Comment